Trial Profile
Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 01 Aug 2018 Results published in the Diabetes Therapy.
- 08 Dec 2017 Results of a post-hoc analysis assessing efficacy and safety of dapagliflozin in real clinical settings (n=2008) presented at the 2017 Congress of the International Diabetes Federation
- 02 Dec 2016 Status changed from active, no longer recruiting to completed.